Latest Headlines

Latest Headlines

Ackman's Valeant ties pay off yet again with Sprout buy

Bill Ackman's relationship with Valeant has paid off big-time since the hedge fund manager first teamed up with the Canadian pharma on its hostile pursuit of Allergan. And this time, it's an investment in Sprout Pharmaceuticals--Valeant's latest pickup--that's bringing in the bucks.

Raptor buys into cystic fibrosis with a $418M deal

Rare disease biotech Raptor Pharmaceutical signed a deal to pay up to $418 million to Tripex Pharmaceuticals in exchange for an inhaled treatment for cystic fibrosis.

GlaxoSmithKline flips an MS project to Novartis for up to $1B

Novartis is paying GlaxoSmithKline as much as $1 billion for the rights to a mid-stage multiple sclerosis treatment, betting it can develop an heir to the blockbuster Gilenya, soon to lose patent protection.

Roche's M&A party rages on with Kapa Biosystems deal

Roche has been hot on the dealmaking trail this past year, snatching up smaller companies to boost its portfolio. In its latest round of M&A, the diagnostics giant is acquiring Kapa Biosystems, getting its hands on the company's next-generation sequencing (NGS) products to further build out its offerings.

U.K. CRO conglomerate bags another testing outfit with eyes on toxicology

Concept Life Sciences, a CRO pieced together through a string of acquisitions, has inked a deal to acquire a toxicology-focused contractor, looking to expand its palate of drug development services.

Valeant sizes up women's health with $1B deal for Sprout and its libido drug

That didn't take long. Just one day after Sprout Pharmaceuticals won a controversial FDA approval for new female libido drug Addyi (flibanserin), serial buyer Valeant has agreed to buy the company.

Controversial Valeant Pharma swoops in with a $1B Addyi buyout

A little more than a day after little Sprout Pharmaceuticals won a controversial FDA approval to market Addyi (flibanserin) as a new drug that can help inspire sexual desire among women, Valeant Pharmaceuticals announced a deal to acquire the one-drug company in a $1 billion buyout.

UPDATED: Horizon puts forth new slate of directors as Depomed shuts down latest bid

Horizon has criticized Depomed's directors for refusing to come to the table, despite its attempts to "engage in good faith" over a combination of the two companies. Now, though, it's got some new directors in mind who it thinks will see things differently.

Moody's ups medical device industry rating to positive amid M&A, new products

The typically conservative credit rating agency Moody's Investors Service has raised its outlook for the U.S. medical products and devices industry to positive from stable. The firm said it expects to see solid earnings growth over the next 12 to 18 months from the industry.

Roche makes another Dx acquisition of genomic reagent player Kapa

Sharpening its edge in diagnostics is core to the revenue growth strategy at Roche. The biopharma's deal activity in the last week is certainly a testament to that. It will acquire Kapa Biosystems, which provides enzyme optimization for next-gen sequencing and PCR.